Efficacy of immunotherapy with PD-1 inhibitor in colorectal cancer: a meta-analysis.

Abstract

Aim: PD-1 inhibitors have a leading role among immunotherapy while its efficacy on colorectal cancer (CRC) patients did not reach consensus and the small sample size remains as a limitation. Therefore, we undertook a meta-analysis on the effects of the monotherapy anti-PD-1 inhibitors in treating metastatic colorectal cancer (mCRC). Materials & methods: We searched databases to identify studies on efficacy of anti-PD-1 inhibitor on CRC. Objectives were objective response rate, progression-free survival rate, disease control rate and overall survival rate with their 95% CI. Results: The overall survival rate at 1-year was 64.2% (95% CI: 0.46-0.83). Disease control rate was 56.5% (CI: 0.27-0.86) and the objective response rate as 19.7% (CI: 0.08-0.32). The 1-year-progression-free survival rate was 38.4% (CI: 0.12-0.66). Sensitivity analysis and subgroup analysis were also conducted. Conclusion: The monotherapy anti-PD-1 inhibitors are effective in treating mCRC and could be a new option for dMMR mCRC patient in first-line treatment.

• Authors: Shengqi He, Dongqing Hu, Haixia Feng, Ye Xue, Jin Jin, Xiaoyan Wang
• Journal: Journal of comparative effectiveness research (J Comp Eff Res) Vol. 9 Issue 18 Pg. 1285-1292 (12 2020) ISSN: 2042-6313 [Electronic] England
• PMID: 33073605 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Immune Checkpoint Inhibitors
• Immunologic Factors

Topics

• Antibodies, Monoclonal (therapeutic use)
• Colorectal Neoplasms (drug therapy, therapy)
• Humans
• Immune Checkpoint Inhibitors (therapeutic use)
• Immunologic Factors
• Immunotherapy (methods)
• Progression-Free Survival